PTLA Portola Pharmaceuticals Inc.

+0.68  (+2%)
Previous Close 33.02
Open 32.98
Price To Book 25.53
Market Cap 2251873328
Shares 66,821,167
Volume 1,070,975
Short Ratio
Av. Daily Volume 1,192,102

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2 updated data due at ASH December 2018 noted ORR 34%; 27% CR and in the PTCL cohort ORR 26%; 7% CR.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
Factor Xa inhibitor reversal agent

Latest News

  1. Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019
  2. Portola Pharmaceuticals: Is It Still a Buy?
  3. See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
  4. Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote
  5. Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more
  6. HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
  7. Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors
  8. Edited Transcript of PTLA earnings conference call or presentation 1-Mar-19 1:30pm GMT
  9. Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference
  10. Portola Pharmaceuticals Inc (PTLA) Q4 2018 Earnings Conference Call Transcript
  11. Why Portola Pharmaceuticals Skyrocketed 15.3% Today
  12. European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent
  13. Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million
  14. Will Portola Pharmaceuticals (PTLA) Report Negative Earnings Next Week? What You Should Know
  15. Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology — New Horizons, Emerging Trends, and Upcoming Developments
  16. Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding
  17. Is There An Opportunity With Portola Pharmaceuticals, Inc.’s (NASDAQ:PTLA) 22.17% Undervaluation?